Cidara Therapeutics Aktie

Cidara Therapeutics' stock climbed to $220.49, marking a 52-week high, driven by Merck's announcement that it intends to acquire Cidara for $221.50 per share (about $9.2 billion). At the center of the deal is the Phase‑3 drug candidate CD388 for influenza. Cidara recently reported no revenue but holds $476 million in cash; analysts mostly downgraded ratings and set price targets at the takeover offer. Data show very high annual returns (1,141.61%) and metrics suggesting overvaluation (price‑to‑book ratio 16.4). » More on de.investing.com